Save Search
Save your searches to access them later
Saved Searches
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Reset All
Filter Icon Filter 1
Search Paper
Cancel
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Reset All
Filter Icon Filter 1
Export
Sort by: Relevance
  • Research Article
  • 10.1016/s0924-977x(25)00794-1
Editorial Board
  • Dec 1, 2025
  • European Neuropsychopharmacology

  • Research Article
  • 10.1016/j.euroneuro.2025.08.402
W40. REFINED MITOCHONDRIAL DNA COPY NUMBER (MTDNA-CN) CALLING AND ANALYSIS PIPELINE REVEALS NUCLEAR GENETIC REGULATION OF MTDNA-CN IN BLOOD AND ITS LACK OF ASSOCIATION WITH MOOD DISORDERS
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Xiaotong Wang + 3 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.394
W31. BENCHMARKING METHODS INTEGRATING GWAS AND SINGLE-CELL TRANSCRIPTOMIC DATA FOR MAPPING TRAIT-CELL TYPE ASSOCIATIONS
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Ang Li + 2 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.265
M69. CYP2D6 AND SCHIZOPHRENIA SYMPTOM SEVERITY
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Arun Tiwari + 6 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.322
T39. POLYGENIC RISK AND CHILDHOOD TRAUMA AS PREDICTORS OF SUICIDE RISK IN BIPOLAR DISORDER
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Alfredo Cuellar-Barboza + 11 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.268
M72. GENOME-SCALE METABOLIC MODELLING LINKS GENETIC VARIATION WITH THE DYSREGULATION OF BRAIN-SPECIFIC METABOLIC PATHWAYS IN SCHIZOPHRENIA
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Georgii Dolgalev + 1 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.381
W16. “SLICING-AND-DICING” THE ALL OF US RESEARCH PROGRAM TO INTERROGATE THE POLYGENIC RELATIONSHIP BETWEEN CANNABIS USE AND SCHIZOPHRENIA
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Hayley Thorpe + 8 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.323
T40. GENETIC CORRELATES FOR MINIMAL AND MAXIMAL PHENOTYPES OF MAJOR DEPRESSION
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Mark Adams + 3 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.447
W90. MAJOR DEPRESSIVE DISORDER AMPLIFIES THE COMBINED EFFECT OF POLYGENIC RISK AND CHILDHOOD TRAUMA ON RISK OF LIFETIME SUICIDE ATTEMPT
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Ian Fischer + 9 more

  • Research Article
  • 10.1016/j.euroneuro.2025.08.319
T36. OFFERING PUBLICLY-FUNDED PHARMACOGENOMIC TESTING FOR MAJOR DEPRESSIVE DISORDER IN BRITISH COLUMBIA, CANADA: RECOMMENDATIONS FROM A PUBLIC DELIBERATION
  • Oct 1, 2025
  • European Neuropsychopharmacology
  • Louisa Edwards + 8 more